MARRA, ANTONIO
MARRA, ANTONIO
Universita' degli Studi di MILANO
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2025 P.P.M. Berton Giachetti, S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M.G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, G. Bianchini, G. Curigliano, C. De Angelis, C. Criscitiello
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact
2025 K. Venetis, C. Frascarelli, L.B. Bielo, G. Cursano, R. Adorisio, M. Ivanova, E. Mane, V. Peruzzo, A. Concardi, M. Negrelli, M. D'Ercole, F.M. Porta, Y. Zhan, A. Marra, D. Trapani, C. Criscitiello, G. Curigliano, E. Guerini-Rocco, N. Fusco
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience
2024 E. Crimini, G. Tini, P. Tarantino, L. Ascione, M. Repetto, P. Beria, A. Ranghiero, A. Marra, C. Belli, C. Criscitiello, A. Esposito, E. Guerini Rocco, M.C.P. Barberis, L. Mazzarella, G. Curigliano
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit
2024 A. Esposito, E. Crimini, C. Criscitiello, C. Belli, R. Scafetta, R. Scalia, G. Castellano, E. Giordano, J. Katrini, L. Ascione, L. Boscolo Bielo, M. Repetto, A. Marra, D. Trapani, G.M. Varano, D. Maiettini, P. Della Vigna, F. Orsi, E. Guerini Rocco, N. Fusco, G. Curigliano
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments
2023 C. Valenza, D. Trapani, S. Gandini, C. Sposetti, L. Boscolo Bielo, A. Marra, T. Giarratano, D. Favero, L. Cortesi, L. Moscetti, M. Pistelli, R. Berardi, A. Zambelli, M. Lambertini, L. Del Mastro, V. Guarneri, C. Vernieri, G. Curigliano
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
2023 G. Antonarelli, B. Taurelli Salimbeni, A. Marra, A. Esposito, M.A. Locatelli, D. Trapani, C. Pescia, N. Fusco, G. Curigliano, C. Criscitiello
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
2023 L. Ascione, E. Crimini, D. Trapani, A. Marra, C. Criscitiello, G. Curigliano
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
2023 E. Zattarin, L. Mariani, A. Menichetti, R. Leporati, L. Provenzano, F. Ligorio, G. Fucà, R. Lobefaro, L. Lalli, A. Vingiani, F. Nichetti, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, C. Corti, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, D. Presti, C. Sposetti, C.A. Giorgi, V. Guarneri, R. Pedersini, A. Losurdo, D. Generali, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
2023 G. Antonarelli, C. Corti, P. Tarantino, B.T. Salimbeni, P. Zagami, A. Marra, D. Trapani, S. Tolaney, J. Cortes, G. Curigliano
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study
2023 S. Morganti, A. Marra, S. Gandini, L. Ascione, M. Ivanova, K. Venetis, E. Sajjadi, P. Zagami, F. Giugliano, B. Taurelli Salimbeni, P.P.M. Berton Giachetti, C. Corti, E. De Camilli, G. Curigliano, N. Fusco, C. Criscitiello
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents
2022 P. Tarantino, O. D'Ecclesiis, E. Nicolò, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M.A. Locatelli, C. Belli, A. Esposito, I. Minchella, S.M. Tolaney, G. Curigliano
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer
2022 S. Morganti, A. Marra, K. Venetis, E. Sajjadi, L. Ascione, C. Corti, P. Zagami, M. Ivanova, L. Zattoni, G. Curigliano, N. Fusco, C. Criscitiello
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)
2021 C. Vernieri, F. Nichetti, L. Lalli, L. Moscetti, C.A. Giorgi, G. Griguolo, A. Marra, G. Randon, C.G. Rea, F. Ligorio, S. Scagnoli, C. De Angelis, C. Molinelli, A. Fabbri, E. Ferraro, D. Trapani, A. Milani, E. Agostinetto, O. Bernocchi, G. Catania, A. Vantaggiato, M. Palleschi, A. Moretti, D. Basile, M. Cinausero, A. Ajazi, L. Castagnoli, S. Lo Vullo, L. Gerratana, F. Puglisi, N. La Verde, G. Arpino, A. Rocca, M. Ciccarese, R. Pedersini, A. Fabi, D. Generali, A. Losurdo, F. Montemurro, G. Curigliano, L. Del Mastro, A. Michelotti, E. Cortesi, V. Guarneri, G. Pruneri, L. Mariani, F. de Braud
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials
2021 C. Criscitiello, A. Marra, S. Morganti, P. Zagami, S. Gandini, A. Esposito, G. Curigliano
Expression of tumor-associated antigens in breast cancer subtypes
2020 G. Curigliano, V. Bagnardi, M. Ghioni, J. Louahed, V. Brichard, F.F. Lehmann, A. Marra, D. Trapani, C. Criscitiello, G. Viale
Pharmacological management of male breast cancer
2020 B.A. Duso, D. Trapani, A. Marra, P. D'Amico, E. Guerini Rocco, N. Fusco, L. Mazzarella, C. Criscitiello, A. Esposito, G. Curigliano
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
2020 F. Pietrantonio, F. Loupakis, G. Randon, A. Raimondi, M. Salati, D. Trapani, F. Pagani, I. Depetris, G. Maddalena, F. Morano, S. Corallo, M. Prisciandaro, F. Corti, V. Guarini, A. Bocconi, A. Marra, C. Belli, A. Spallanzani, M. Fassan, S. Lonardi, G. Curigliano, G. Fucà, M. Di Bartolomeo, F. de Braud
T cell Bispecific Antibodies to Bypass MHC Class I Loss in Breast Cancer
2019 A. Marra, G. Curigliano
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
2019 A. Marra, G. Curigliano
Long-term disease-free survival in surgically-resected oral tongue cancer: a 10-year retrospective study
2019 A. Marra, M. Violati, F. Broggio, C. Codecà, M. Blasi, A. Luciani, S. Zonato, D. Rabbiosi, L. Moneghini, A. Saibene, A. Maccari, G. Felisati, D. Ferrari